TENAX THERAPEUTICS, INC.

TENX

Explore Our Financial Data > Companies > TENAX THERAPEUTICS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
TENX
CIK0000034956
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517
Website tenaxthera.com
Phone919-855-2100
CEOChristopher T. Giordano
Employees9

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-52.60 million
Net Income$-52.60 million
Net Income to Common$-52.60 million
EPS$-1.34
View All
Balance Sheet
Cash$97.56 million
Assets$104.23 million
Liabilities$7.16 million
Common Equity$97.07 million
Liabilities & Equity$104.23 million
View All
Cash Flow Statement
Net Income$-52.60 million
Cash From Operating Activities$-35.80 million
Cash From Investing Activities$0.00
Cash From Financing Activities$38.51 million
Change in Cash$2.71 million
View All
Calculations
NOPAT$-39.47 million
EBITDA$-56.42 million
Price to EarningsN/A
Price to Book$2.12
ROEN/A
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical ope

Article Link

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Mr. Healey is a seasoned pharmaceutical executive with a strong track record of successful commercial leadership experienceCHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately.

Article Link

Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Tenax Therapeutics...

Article Link

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25

Article Link

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls

Article Link